Introduction For the purpose of blocking transmission of Plasmodium falciparum malaria from humans to mosquitoes, a single dose of primaquine is recommended by the World Health Organisation as an addition to artemisinin combination therapy. Primaquine clears gametocytes but causes dosedependent haemolysis in individuals with glucose-6-phosphate dehydrogenase deficiency. Evidence is needed to inform the optimal dosing of primaquine for malaria elimination programmes and for the purpose of interrupting the spread of artemisinin-resistant malaria. This study investigates the efficacy and safety of reducing doses of primaquine for clearance of gametocytes in participants with normal G6PD status.
Strengths and limitations of this study
For ethical reasons, in this trial, dose-finding is conducted in children with normal G6PD status, but, ultimately, information is needed on the safety of lower doses in people with G6PD deficiency.
This trial measures primaquine's transmission-blocking potential by assessing gametocyte clearance.
Endpoints of mosquito transmission at multiple timepoints could be usefully assessed but on smaller numbers of individuals.
BACKGROUND
Sustained deployment of vector control measures and accessible, effective drug therapy has reduced the transmission of Plasmodium falciparum in many endemic countries. However, further scaling-up of currently available malaria control measures is unlikely to achieve malaria elimination in most settings [1] . Moreover, the emergence of resistance to artemisinin in Southeast Asia [2 3] , and the development of insecticide resistance and adaptive behaviour in the mosquito vector [4-6] present significant threats to the current trend of declining malaria burden. Malaria elimination initiatives and artemisinin-resistance containment strategies both require additional tools that are specifically aimed at reducing the transmission of malaria parasites [7 8 ].
Antimalarial drugs are designed primarily to target the asexual stages of the parasite that cause morbidity and mortality. The effect of antimalarial drugs on gametocytes, the transmission stages, has for decades been seen as ancillary. P. falciparum gametocytes undergo complex development that is biting female Anopheles mosquitoes [13 14] .The majority of antimalarial drugs, including artemisinins, lumefantrine and piperaquine, have some efficacy against immature gametocytes [15 16 ]. These drugs have the potential to reduce transmission at a population level because asexual parasites are cleared, preventing de novo development of gametocytes, and fewer of the immature gametocytes that are present upon initiation of treatment survive to maturity. However, the vast majority of symptomatic cases have measurable and transmissible levels of mature gametocytes at presentation [17 18 ]. These persist after treatment with all antimalarials that are currently implemented as first-line treatment, including artemisinin combination therapy (ACT). Gametocytes that persist after ACT have repeatedly been shown to be infectious to mosquitoes [17 19 20] . This post-treatment gametocyte carriage frequently occurs at low densities, commonly below the microscopic threshold for detection [21 22 ], but is sufficiently high for efficient mosquito infection [17 23 ].
The only class of drugs that are effective against mature P. falciparum gametocytes is the 8-aminoquinolines. Primaquine is the most widely available drug in this class. The exact mechanism for this gametocytocidal activity is unknown, but it is probably dependent on oxidative damage to the intraerythrocytic parasite by primaquine metabolites[24] Primaquine as single dose of 0.75mg base/kg added to standard artemisinin containing therapy (ACT) has superior gametocytocidal activity to ACT alone [25] [26] [27] . All doses of primaquine described hereafter refer to the dose of primaquine base per unit weight. There are indications that doses of primaquine lower than 0.75mg /kg may be equally 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
METHODS AND ANALYSIS

Study design
The study is a prospective, randomised, parallel arm, placebo-controlled, double-blinded clinical trial of reducing doses of primaquine administered with artemether lumefantrine (AL) for the treatment of uncomplicated clinical P. falciparum malaria infection in children aged 1-10 years of age. The study uses a non-inferiority design to evaluate the efficacy and a superiority design to evaluate the safety of 0.1mg/kg and 0.4 mg/kg primaquine compared to 0.75mg/kg when added to AL. 
Study objectives
Participants and enrolment
The study is conducted at Walukuba Health Centre IV in Walukuba sub-county, Jinja district, in eastern Uganda. In this area, malaria transmission is year-round with two seasonal peaks. The entomological 
Randomization, blinding and intervention
After enrolment (day 0), participants are randomised to a treatment arm stratified by gender ( Figure 2 ).
The study pharmacist selects sequential opaque envelopes (from either the male or the female pile).
Each envelope contains a pre-determined treatment assignment code. The study pharmacist is the only member of the clinic team not blinded to the treatment arm and is not involved in assessing patients or assigning outcomes. All study site staff who administer drugs, assess patients and process laboratory samples do not have access to the randomization code breaker.
All participants receive a three day course of artemether lumefantrine according to Ugandan national treatment guidelines for uncomplicated malaria. Participants are randomised to receive a placebo or a dose of 0.1mg/kg, 0.4 mg/kg or 0.75g mg/kg primaquine in addition to the AL treatment. The dose of 
Follow up measurements
Study participants are reviewed on days 0, 1, 2, 3, 7, 10, 14, 21, 28 after enrolment or on any day of illness. On each of the scheduled visit days they are assessed clinically with standardised adverse event recording and blood samples are taken for microscopical detection of asexual parasites and gametocytes, molecular detection of gametocytes and haemoglobin measurements ( Table 1) . Haemoglobin is measured on days 0, 1, 2, 3, 7, 10, 14, 21 and 28 using HemoCue 201+ photometers (HemoCue; Angelholm, Sweden). At each follow up visit, study staff assess participants in an objective manner according to a clinical record form and assessment for adverse events is conducted in a prospective, systematic fashion at all visits, including the enrolment visit (e.g. vomiting post AL). All data are double-entered in real time.
Safety considerations
A protocol was developed in order to standardise the detection, investigation and management of severe haemolysis in this trial (Figures 3 and 4) . A Data Safety Monitoring Board (DSMB) has been 
Ethical considerations
The study protocol and informed consent forms were approved by the Makerere University School of Advisory Committee for the study agreed to meet at predetermined stages of the study. Before the study began, local community stakeholders (including village health team and local council members) in
Walukuba were consulted and a community advisory board meeting was held.
Sample size
For efficacy, the sample size calculation is based on non-inferiority of each of the two test dose arms to the comparator arm, the WHO-recommended dose of primaquine, 0.75mg/kg. The primary outcome measure is number of days to gametocyte clearance. The addition of primaquine (0.75mg/kg) to ACT in Tanzania reduced the time to gametocyte clearance from 28.6 to 6.3 days (standard deviation 6 days) [41] . Allowing for a 10% loss to follow up, a sample size of 120 per arm will provide over 80%
power at the 0.05 significance level to detect non-inferiority to the standard arm with a non-inferiority margin of 2.5 days, which was considered to be a clinically relevant reduction in gametocyte clearance time. This sample size also allows for an analysis of superiority of the efficacy of the two test dose arms to placebo. 
Data analysis
Data will be double entered in Microsoft Access and imported into Stata version 12.0 (Statacorp Ltd, Texas, US). All efficacy analyses will be based on gametocyte detection by Pfs25 QT-NASBA. Gametocyte density on days 7, 10 and 14 will be compared with the comparator arm (0.75mg primaquine/kg) by chisquare test. The mean duration of gametocyte carriage and 95% confidence interval will be estimated in each treatment arm and compared with the comparator arm using a previously validated mathematical model [42] . The area under the curve (AUC) of gametocyte density over time will be calculated using the method described by Mendez et al. [43] . For individuals who are gametocyte positive at enrolment, Kaplan-Meier survival analysis will be used to compare the decline in gametocyte prevalence.
The primary safety outcome, mean maximal fall in haemoglobin concentration during 28 days of follow up will be assessed for each treatment arm. Pair-wise comparisons will be made between each of the treatment arms and compared with the comparator arm using unpaired t-tests.
DISCUSSION
In the 2010 edition of the Guidelines for the Treatment of Malaria, the World Health Organisation (WHO) recommends that a single dose of 0.75mg/kg primaquine is added to ACT in malaria elimination potential involves assessing the infectiousness of the participant's blood to mosquitoes using the membrane feeding assay or direct skin feeding assays[57], the latter being described by early malariologists[58 59]. However, the capacity for mosquito feeding assays is not widely available and repeated assessments of infectiousness on the same patients have never been performed as part of clinical trials. This is partly because of ethical concerns related to repeated venous bleeding in young children, and partly because of the complexity of mosquito husbandry when large numbers of mosquitoes are required for robust transmission estimates [60] . In the absence of biomarkers, using the prevalence and density of gametocytes after treatment is the most pragmatic approach to assess the transmission blocking efficacy of drugs across a variety of malaria endemic settings.
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